The present invention relates to an
oncolytic virus and the use thereof, and specifically, an
oncolytic virus having suppressed expression of a
thymidine kinase (TK)
gene and comprising genes encoding
granulocyte-macrophage colony-stimulating factor (GM-CSF) and a complement regulatory
protein; and the use of such a
oncolytic virus . The oncolytic
virus of the present invention maintains its
efficacy even upon intravenous injection, and thus, it may also be applied to the treatment of various
solid carcinomas and metastatic cancers in addition to superficial
solid cancers. In addition, the oncolytic
virus of the present invention acquires resistance to the
attack of the body's
complement system by expressing a complement regulatory
protein on the surface of the
virus, and thus, it is stable in the blood, and it maintains stable oncolytic activity upon intravenous injection, and thus, it may reduce the
dose of the virus to minimize the side effects of anti-
cancer drugs. Therefore, the oncolytic virus of the present invention may be usefully used for preventing or treating
cancer.